Verrica Pharmaceuticals Inc. (NASDAQ:VRCA)
| Market Cap | 71.12M-6.3% |
| Revenue (ttm) | 30.32M+106.2% |
| Net Income | -31.18M+35.8% |
| EPS | -1.74+79.0% |
| Shares Out | 17.18M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 47,552 |
| Open | 4.30 |
| Previous Close | 4.21 |
| Day's Range | 4.06 - 4.32 |
| 52-Week Range | 3.28 - 9.82 |
| Beta | 1.61 |
| Analysts | Buy |
| Price Target | 9.00(+117.39%) |
| Earnings Date | Nov 13, 2026 |
Verrica Pharmaceuticals Inc. has a live Insider Score.
Scored on 6 qualifying trades from 4 insiders in the last 90 days.
About VRCA
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$VRCA stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in VRCA holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by VRCA's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
VRCA Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New VRCA patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to VRCA from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in VRCA
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $1.18M |
| VXFVanguard Extended Market ETF | $739.64K |
| IWCiShares Micro-Cap ETF | $132.04K |
| AVTMAvantis Total Equity Markets ETF 1 | $2.03K |
Estimated from each fund’s disclosed top holdings × AUM
VRCA Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from VRCA’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score